Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.

ABSTRACT:

Background

The role of piperacillin/tazobactam for treatment of serious infections due to AmpC-producing organisms remains debatable, particularly in immunocompromised patients.

Methods

This was a retrospective cohort study in immunocompromised patients that investigated the effect of definitive treatment with either piperacillin/tazobactam versus cefepime or carbapenems for bacteraemia caused by cefoxitin-non-susceptible Enterobacterales. The primary endpoint was a composite of clinical and microbiological failure. A logistic regression model was constructed to assess the impact of definitive treatment choice on the primary endpoint.

Results

A total of 81 immunocompromised patients with blood cultures positive for cefoxitin-non-susceptible Enterobacterales were inclu

SUBMITTER: Lu B 

PROVIDER: S-EPMC10068414 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature